Monoclonal antibody cocktail cut COVID-19 hospitalization, death by 70% in outpatient setting
A cocktail of two monoclonal antibodies — casirivimab and imdevimab — significantly reduced the risk for hospitalization or death in nonhospitalized patients with COVID-19, according to results of a phase 3 pivotal trial.Casirivimab with imdevimab (REGEN-COV, Regenerson) also shortened symptom duration and reduced viral load, researchers reported during a breaking news session at the